KEGG   DRUG: Trastuzumab emtansine
Entry
D09980                      Drug                                   
Name
Trastuzumab emtansine (USAN/INN);
Trastuzumab emtansine (genetical recombination) (JAN);
Ado-trastuzumab emtansine;
Kadcyla (TN)
Product
KADCYLA (Genentech)
Formula
C6448H9948N1720O2012S44
Exact mass
145075.67
Mol weight
145165.1575
Class
Antineoplastic
 DG01918  Tyrosine kinase inhibitor
  DG01917  Receptor tyrosine kinase inhibitor
   DG03158  HER2 inhibitor
Remark
Therapeutic category: 4291
ATC code: L01FD03
Product: D09980<JP/US>
Efficacy
Antineoplastic, Tubulin polymerization inhibitor, Receptor tyrosine kinase inhibitor, Anti-HER2 antibody
  Disease
Breast cancer (HER2 positive) [DS:H00031]
  Type
Antibody-drug conjugate
Target
ERBB2* (HER2, CD340) [HSA_VAR:2064v1 2064v3] [HSA:2064] [KO:K05083]
TUBB [HSA:10381 10382 10383 203068 347688 347733 7280 81027 84617] [KO:K07375]
  Pathway
hsa04012  ErbB signaling pathway
hsa05200  Pathways in cancer
hsa05224  Breast cancer
  Network
nt06270  Breast cancer
Interaction
Structure map
map07045  Antineoplastics - protein kinase inhibitors
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
  L01 ANTINEOPLASTIC AGENTS
   L01F MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
    L01FD HER2 (Human Epidermal Growth Factor Receptor 2) inhibitors
     L01FD03 Trastuzumab emtansine
      D09980  Trastuzumab emtansine (USAN/INN) <JP/US>
USP drug classification [BR:br08302]
 Antineoplastics
  Monoclonal Antibody/Antibody-Drug Conjugate
   Ado-Trastuzumab Emtansine
    D09980  Trastuzumab emtansine (USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
 4  Agents affecting cellular function
  42  Antineoplastics
   429  Miscellaneous
    4291  Other Antitumors
     D09980  Trastuzumab emtansine (USAN/INN); Trastuzumab emtansine (genetical recombination) (JAN)
Drug groups [BR:br08330]
 Antineoplastic
  DG01918  Tyrosine kinase inhibitor
   DG01917  Receptor tyrosine kinase inhibitor
    DG03158  HER2 inhibitor
     D09980  Trastuzumab emtansine
Drug classes [BR:br08332]
 Antineoplastic
  DG03158  HER2 inhibitor
   D09980  Trastuzumab emtansine
Target-based classification of drugs [BR:br08310]
 Protein kinases
  Receptor tyrosine kinases (RTK)
   EGFR family
    ERBB2* (HER2, CD340) [HSA_VAR:2064v1 2064v3]
     D09980  Trastuzumab emtansine (USAN/INN) <JP/US>
 Not elsewhere classified
  Cellular process
   Cytoskeleton
    TUBB
     D09980  Trastuzumab emtansine (USAN/INN) <JP/US>
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D09980
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D09980
New drug approvals in Japan [br08318.html]
 Drugs with new active ingredients
  D09980
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D09980
Pharmacogenomic biomarkers [br08341.html]
 Somatic variations in targeted cancer therapies
  D09980
Other DBs
CAS: 1018448-65-1
PubChem: 135626701

» Japanese version   » Back

  All links  
Ontology (11)   
   KEGG BRITE (11)   
Pathway (1)   
   KEGG PATHWAY (1)   
Network (2)   
   KEGG VARIANT (2)   
Disease (1)   
   KEGG DISEASE (1)   
Drug (1)   
   KEGG DGROUP (1)   
Chemical substance (1)   
   PubChem (1)   
Gene (12)   
   KEGG ORTHOLOGY (2)   
   KEGG GENES (10)   
All databases (29)   

Download RDF
DBGET integrated database retrieval system